

# Financial Highlights

---

Euro million

	Q1 '01	Δ %
▲ Sales	7,901	+ 7.8
▲ Sales (cont.)	7,662	+ 10.1
▼ Operating income	848	- 18.0
▼ Operating income pre-exceptionals (cont.)	936	- 6.9
▼ Non-operating result	- 126	- 53.7
▼ Pre-tax income	722	- 24.2
▼ After-tax income	438	- 21.8
▼ Net income	442	- 20.5
▼ Earnings/share (Euro)	0.61	- 19.7

# Components of Q1 Sales Trend

Euro million

	2000	2001	Δ %		
Sales	7,331	7,901	+ 7.8		
• Discontinuing	369	239			
• Continuing	6,962				
+ Acquisitions/ Divestitures		427	+ 6.1	Acquisitions	+ 439
				• Lyondell	+ 202
				• CSM	+ 35
				• Misung	+ 22
				• Sybron	+ 70
				• Cytec	+ 26
				• Others	+ 84
				Divestitures	- 12
				• Biologicals	- 12
+ Currencies		+ 90	+ 1.3		
+ Prices		+ 420	+ 6.0		
+ Volumes		- 237	- 3.4		
• Continuing		7,662	+ 10.1		

# Q1 Comparable Operating Income

Euro million

	2001	2000	Δ %
<b>OPI reported</b>	<b>848</b>	<b>1,034</b>	– 18.0
● Segments	897	1,019	– 12.0
● Reconciliation	(49)	(18)	
● Discontinuing operations	0	(33)	
– Fibers	(15)*	16	
– Erdölchemie	15	14	
– DyStar	•	3	
<b>OPI continuing</b>	<b>848</b>	<b>1,001</b>	– 15.3
● Exceptional items (cont.)	88	4	
<b>OPI underlying – continuing operations</b>	<b>936</b>	<b>1,005</b>	– 6.9


\* including – 17 exceptionals, previous year = (0)

# Q1 Exceptional Items

Euro million	2001			2000			Δ %
	Charge	Gain	Net	Charge	Gain	Net	
Health Care	14	0	- 14	35	10	- 25	+ 11
Agriculture	0	0	0	5	0	- 5	+ 5
Polymers	18	0	- 18	7	0	- 7	- 11
Chemicals	51	0	- 51	1	0	- 1	- 50
Reconciliation	5	0	- 5	0	34	+ 34	- 39
Discont.	17	0	- 17	0	0	0	- 17
Total	105	0	- 105	48	44	- 4	-101

# Q1 '01 Business Performance

Euro million



\* as reported

# Pharmaceuticals – Top 10 Products

Euro million

		Q1'01	Δ %
(1)	Ciprobay	336	- 24
(2)	Adalat	268	- 8
(3)	Lipobay/Baycol	247	+ 88
(4)	Glucobay	75	+ 3
(5)	Avelox	72	+ 150
(6)	Gamimune	61	+ 16
(7)	Kogenate	47	- 49
(8)	Trasylol	37	+ 36
(9)	Prolastin	32	+ 1
(10)	Nimotop	30	- 11